BCLI

0.753010.36%
HH

Hartoun Hartounian

Executive VP & COO

Dr. Hartoun Hartounian, also known as Haro, Ph.D., is EVP and COO at Brainstorm Cell Therapeutics Inc. since June 18, 2024 and joined in June 2024. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility. Dr. Hartounian founded and managed the growth of four biotechnology companies. He has a track record of achieving aggressive goals at large pharmaceutical, contract development and manufacturing organizations, as well as at start-up biotechnology companies. In his new role, Dr. Hartounian oversees all operational aspects of BrainStorm Cell Therapeutics, including CMC and commercialization. He served initially as the BioCentriq's General Manager (June 2015 to May 2022) and was its President, CEO and a member of the Board of Directors (May 2022 to December 2023). He served as the President of Vyteris, Inc. since May 2008 and served as its Chief Executive Officer from December 2008 to August 9, 2011. From September 2011 to February 2013, he was CEO and Co-Founder of Allied BioVentures. Dr. Hartounian served as Chief Executive Officer and President of Executive Director of DiaVacs Inc. from February 2013 to April 2015. Dr. Hartounian served as Chief Technology Officer of Vyteris Inc. since November 27, 2007 and was responsible for ongoing research and development for Vyteris' proprietary iontophoretic transdermal patch system, otherwise known as Smart Patch. Dr. Hartounian is a Biotechnology & Pharmaceutical executive with a record of achieving aggressive goals by positioning capital, people, intellectual property, systems and internal disciplines for successful long term growth. He founded Protagenic Therapeutics Inc. in 2006 and served as its Chief Executive Officer. He served as the President and Chief Operating Officer of MicroIslet Inc. from April 2002 to February 17, 2006 and MSLT Delaware from August 2000 to April 2002. He served as the Head of the Process Development at Kelco BioPolymers from July 1998 to August 2000. Between 1998 and 2001, Dr. Hartounian served as Director of Process Development at Monsanto where he steered process R&D, formulation development, analytical method development and cGMP sourcing for a multi functional nutritional project. From April 1994 to June 1998, he served as an Associate Director of Product Development at SkyePharma Plc (formerly, Depotech Corp.), where he was responsible for all aspects of Product Development, scale up and technology transfer and was the key contributor in the commercialization of SkyePharma's first product. Dr. Hartounian is a member of an investment organization called the Tech Coast Angels in San Diego. He had been a Director of Vyteris, Inc. since November 2008 to September 2011. He serves as a Director of Protagenic Therapeutics Inc. He serves as an of Executive Director of DiaVacs Inc. He served as a Director of Atrinsic, Inc. He served as a Director of MicroIslet Inc. from April 2002 to February 17, 2006. Further, Dr. Hartounian has been an affiliated faculty member at the New Jersey Institute of Technology in the Department of Chemistry and Environmental Sciences since April 2020, as well as an adjunct faculty member in the Department of Chemical Engineering at Columbia University from March 2015 to May 2022. He serves as adjunct faculty of Drexel University, in Philadelphia and a lecturer at the Bioengineering Department at the University of California, San Diego. Dr. Hartounian received his PhD in Chemical Engineering and a minor in Biochemistry from the University of Delaware in 1992 and an MS in Chemical Engineering from UCLA and a B.S. in Chemical Engineering from Arya-Mehr University.

Positions